BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33274565)

  • 1. LINC00261/microRNA-550a-3p/SDPR axis affects the biological characteristics of breast cancer stem cells.
    Li Y; Wu C
    IUBMB Life; 2021 Jan; 73(1):188-201. PubMed ID: 33274565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA NORAD inhibition upregulates microRNA-323a-3p to suppress tumorigenesis and development of breast cancer through the PUM1/eIF2 axis.
    Shi P; Zhang J; Li X; Li W; Li H; Fu P
    Cell Cycle; 2021 Jul; 20(13):1295-1307. PubMed ID: 34125645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA (LncRNA) CASC9/microRNA(miR)-590-3p/sine oculis homeobox 1 (SIX1)/NF-κB axis promotes proliferation and migration in breast cancer.
    Chang J; Zhang Y; Ye X; Guo H; Lu K; Liu Q; Guo Y
    Bioengineered; 2021 Dec; 12(1):8709-8723. PubMed ID: 34711117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2.
    Chen Y; Wu N; Liu L; Dong H; Liu X
    J Cell Mol Med; 2020 Jul; 24(13):7353-7369. PubMed ID: 32558224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
    Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
    J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.
    Lin QY; Wang JQ; Wu LL; Zheng WE; Chen PR
    Breast Cancer; 2020 Jan; 27(1):147-158. PubMed ID: 31410735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circular RNA CNOT2 knockdown regulates twist family BHLH transcription factor via targeting microRNA 409-3p to prevent breast cancer invasion, migration and epithelial-mesenchymal transition.
    Su Q; Shen H; Gu B; Zhu N
    Bioengineered; 2021 Dec; 12(1):9058-9069. PubMed ID: 34698000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.
    Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M
    J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC00261 inhibits progression of pancreatic cancer by down-regulating miR-23a-3p.
    Wang X; Gao X; Tian J; Zhang R; Qiao Y; Hua X; Shi G
    Arch Biochem Biophys; 2020 Aug; 689():108469. PubMed ID: 32590069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2.
    Ho JY; Hsu RJ; Wu CH; Liao GS; Gao HW; Wang TH; Yu CP
    Oncotarget; 2016 Aug; 7(33):53853-53868. PubMed ID: 27462780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA RP11-283G6.5 confines breast cancer development through modulating miR-188-3p/TMED3/Wnt/β-catenin signalling.
    Pei J; Zhang S; Yang X; Han C; Pan Y; Li J; Wang Z; Sun C; Zhang J
    RNA Biol; 2021 Oct; 18(sup1):287-302. PubMed ID: 34130584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1.
    Zhai S; Xu Z; Xie J; Zhang J; Wang X; Peng C; Li H; Chen H; Shen B; Deng X
    Oncogene; 2021 Jan; 40(2):277-291. PubMed ID: 33122827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M2 Macrophage-Derived Exosomes Regulate miR-199a-3p Promoter Methylation Through the LINC00470-Mediated myc/DNMT3a Axis to Promote Breast Cancer Development.
    Ma D; Wu J; Chen C; Niu Y; Ji K; Xiao Y; Guan Q
    Biochem Genet; 2024 Jun; 62(3):2082-2099. PubMed ID: 37851210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro.
    Troschel FM; Böhly N; Borrmann K; Braun T; Schwickert A; Kiesel L; Eich HT; Götte M; Greve B
    Tumour Biol; 2018 Aug; 40(8):1010428318791887. PubMed ID: 30091683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LINC00261 suppresses human colon cancer progression via sponging miR-324-3p and inactivating the Wnt/β-catenin pathway.
    Yan D; Liu W; Liu Y; Luo M
    J Cell Physiol; 2019 Dec; 234(12):22648-22656. PubMed ID: 31183860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis.
    Zhao P; Guan H; Dai Z; Ma Y; Zhao Y; Liu D
    Eur J Pharmacol; 2019 Dec; 865():172778. PubMed ID: 31705901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.
    Sun T; Song Y; Yu H; Luo X
    Cancer Biol Ther; 2019; 20(6):760-773. PubMed ID: 30810442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-140-3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan-4.
    Onyeisi JOS; Greve B; Espinoza-Sánchez NA; Kiesel L; Lopes CC; Götte M
    J Cell Biochem; 2021 Oct; 122(10):1491-1505. PubMed ID: 34180077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR-363-3p.
    Rong H; Chen B; Wei X; Peng J; Ma K; Duan S; He J
    Thorac Cancer; 2020 Mar; 11(3):659-671. PubMed ID: 31968395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.